

BIOCRYST PHARMACEUTICALS INC

Form 4

March 07, 2014

**FORM 4**
**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Babu Yarlagadda S

2. Issuer Name **and** Ticker or Trading  
Symbol  
BIOCRYST PHARMACEUTICALS  
INC [BCRX]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
4505 EMPEROR BLVD., SUITE  
200

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/01/2014

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_X\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
Senior VP - Drug Discovery

(Street)  
DURHAM, NC 27703

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |                     |            | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---------------------|------------|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount              | (A) or (D) | Price   |  |   |
| Common Stock                    | 03/01/2014                           |  | F                              |   | 1,618<br><u>(1)</u> | D          | \$ 11.69  | 220,021  | D   |
| Common Stock                    | 03/04/2014                           |  | M                              |   | 2,208               | A          | \$ 8.83   | 222,229  | D   |
| Common Stock                    | 03/04/2014                           |  | M                              |   | 2,929               | A          | \$ 4.3  | 225,158  | D   |
| Common Stock                    | 03/04/2014                           |  | M                              |   | 23,679              | A          | \$ 8.83   | 248,837  | D   |
| Common Stock                    | 03/04/2014                           |  | S                              |   | 40,642              | D          | \$ 12.57  | 208,195  | D   |

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount<br>Underlying Security<br>(Instr. 3 and 4) | 8. Amount or Number of Securities |
|---|--|---|---|--------------------------------------|--|--|--|-----------------------------------|
|   |  |   |   | Code                                 | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date   | Title                             |
| Non-Qualified<br>Stock Option                       | \$ 8.83  | 03/04/2014                              |   | M                                    | 2,208  | 05/12/2005   | 05/12/2014   | Common<br>Stock                   |
| Non-Qualified<br>Stock Option                       | \$ 4.3   | 03/04/2014                              |   | M                                    | 2,929  | 05/11/2006   | 05/11/2015   | Common<br>Stock                   |
| Emp. Stock<br>Option (Right<br>to Buy)              | \$ 8.83  | 03/04/2014                              |   | M                                    | 23,679   | 05/12/2005   | 05/12/2014   | Common<br>Stock                   |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships                    |
|--|----------------------------------|
|  | Director 10% Owner Officer Other |
| Babu Yarlagadda S<br>4505 EMPEROR BLVD.<br>SUITE 200<br>DURHAM, NC 27703 | Senior VP - Drug Discovery       |

## Signatures

/s/ Alane P. Barnes, by power of  
attorney

03/07/2014

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Shares withheld by BioCryst Pharmaceuticals, Inc. upon the vesting of restricted stock to satisfy the reporting person's tax withholding obligations.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$12.43 to \$13.00. The

- (2) reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.